Danaher Corp. (DHR)

$236.36

-3.03

(-1.27%)▲

Market is closed - opens 7 PM, 19 Apr 2024
star icon

Danaher Corporation is a global science and technology company that designs, manufactures, and markets a range of products and services.

Insights on Danaher Corp.

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 8.36B → 2.69B (in $), with an average decrease of 19.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.12B → 1.07B (in $), with an average decrease of 4.4% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 18.6%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 6.9%

Performance

  • $232.22
    $238.37
    $236.36
    downward going graph

    1.75%

    Downside

    Day's Volatility :2.58%

    Upside

    0.84%

    downward going graph
  • $181.70
    $268.71
    $236.36
    downward going graph

    23.13%

    Downside

    52 Weeks Volatility :32.38%

    Upside

    12.04%

    downward going graph

Returns

PeriodDanaher Corp.Sector (Health Care)S&P500
3 Months
5.78%
-0.7%
5.0%
6 Months
16.89%
6.6%
16.4%
1 Year
-6.54%
3.7%
20.9%
3 Years
-1.07%
14.0%
20.0%

Highlights

Market Capitalization
178.0B
Book Value
$72.36
Dividend Share
1.05
Dividend Yield
0.45%
Earnings Per Share (EPS)
5.65
PE Ratio
42.54
PEG Ratio
3.13
Wall Street Target Price
264.26
Profit Margin
19.94%
Operating Margin TTM
20.87%
Return On Assets TTM
3.98%
Return On Equity TTM
8.15%
Revenue TTM
23.9B
Revenue Per Share TTM
32.44
Quarterly Revenue Growth YOY
-23.5%
Gross Profit TTM
18.9B
EBITDA
7.5B
Diluted Eps TTM
5.65
Quarterly Earnings Growth YOY
-0.51
EPS Estimate Current Year
7.62
EPS Estimate Next Year
8.68
EPS Estimate Current Quarter
1.76
EPS Estimate Next Quarter
1.66

Analyst Recommendation

Buy
    79%Buy
    20%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Danaher Corp.(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
23
Hold
6
6
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11.8%

Current $236.36
Target $264.26

Company Financials

FY18Y/Y Change
Revenue
19.9B
↑ 8.53%
Net Income
2.7B
↑ 6.37%
Net Profit Margin
13.33%
↓ 0.27%
FY19Y/Y Change
Revenue
17.9B
↓ 9.96%
Net Income
3.0B
↑ 13.48%
Net Profit Margin
16.8%
↑ 3.47%
FY20Y/Y Change
Revenue
22.3B
↑ 24.41%
Net Income
3.6B
↑ 21.2%
Net Profit Margin
16.36%
↓ 0.44%
FY21Y/Y Change
Revenue
29.5B
↑ 32.17%
Net Income
6.4B
↑ 76.44%
Net Profit Margin
21.84%
↑ 5.48%
FY22Y/Y Change
Revenue
31.5B
↑ 6.85%
Net Income
7.2B
↑ 12.06%
Net Profit Margin
22.91%
↑ 1.07%
FY23Y/Y Change
Revenue
14.0B
↓ 55.41%
Net Income
4.7B
↓ 34.21%
Net Profit Margin
33.8%
↑ 10.89%
Q3 FY22Q/Q Change
Revenue
7.7B
↓ 1.14%
Net Income
1.6B
↓ 6.45%
Net Profit Margin
20.24%
↓ 1.15%
Q4 FY22Q/Q Change
Revenue
8.4B
↑ 9.21%
Net Income
2.2B
↑ 43.91%
Net Profit Margin
26.67%
↑ 6.43%
Q1 FY23Q/Q Change
Revenue
7.2B
↓ 14.36%
Net Income
1.5B
↓ 35.04%
Net Profit Margin
20.23%
↓ 6.44%
Q2 FY23Q/Q Change
Revenue
7.2B
↓ 0.14%
Net Income
1.1B
↓ 23.72%
Net Profit Margin
15.45%
↓ 4.78%
Q3 FY23Q/Q Change
Revenue
6.9B
↓ 3.97%
Net Income
1.1B
↑ 2.08%
Net Profit Margin
16.43%
↑ 0.98%
Q4 FY23Q/Q Change
Revenue
2.7B
↓ 60.82%
Net Income
1.1B
↓ 4.43%
Net Profit Margin
40.07%
↑ 23.64%
FY18Y/Y Change
Total Assets
47.8B
↑ 2.54%
Total Liabilities
19.6B
↓ 3.33%
FY19Y/Y Change
Total Assets
62.1B
↑ 29.79%
Total Liabilities
31.8B
↑ 62.2%
FY20Y/Y Change
Total Assets
76.2B
↑ 22.68%
Total Liabilities
36.4B
↑ 14.42%
FY21Y/Y Change
Total Assets
83.2B
↑ 9.22%
Total Liabilities
38.0B
↑ 4.46%
FY22Y/Y Change
Total Assets
84.4B
↑ 1.4%
Total Liabilities
34.3B
↓ 9.86%
FY23Y/Y Change
Total Assets
84.5B
↑ 0.16%
Total Liabilities
31.0B
↓ 9.52%
Q3 FY22Q/Q Change
Total Assets
81.0B
↓ 0.95%
Total Liabilities
34.0B
↓ 3.32%
Q4 FY22Q/Q Change
Total Assets
84.4B
↑ 4.1%
Total Liabilities
34.3B
↑ 0.66%
Q1 FY23Q/Q Change
Total Assets
85.0B
↑ 0.82%
Total Liabilities
33.6B
↓ 2.06%
Q2 FY23Q/Q Change
Total Assets
84.9B
↓ 0.16%
Total Liabilities
33.2B
↓ 1.12%
Q3 FY23Q/Q Change
Total Assets
87.7B
↑ 3.34%
Total Liabilities
35.3B
↑ 6.45%
Q4 FY23Q/Q Change
Total Assets
84.5B
↓ 3.7%
Total Liabilities
31.0B
↓ 12.23%
FY18Y/Y Change
Operating Cash Flow
4.0B
↑ 15.65%
Investing Cash Flow
-2.9B
↑ 249.7%
Financing Cash Flow
-797.0M
↓ 74.28%
FY19Y/Y Change
Operating Cash Flow
4.0B
↓ 1.75%
Investing Cash Flow
-1.2B
↓ 58.02%
Financing Cash Flow
16.4B
↓ 2153.44%
FY20Y/Y Change
Operating Cash Flow
6.2B
↑ 57.1%
Investing Cash Flow
-21.2B
↑ 1615.45%
Financing Cash Flow
1.0B
↓ 93.85%
FY21Y/Y Change
Operating Cash Flow
8.4B
↑ 34.63%
Investing Cash Flow
-13.0B
↓ 38.85%
Financing Cash Flow
1.3B
↑ 28.73%
FY22Y/Y Change
Operating Cash Flow
8.5B
↑ 1.93%
Investing Cash Flow
-2.2B
↓ 82.8%
Financing Cash Flow
-2.6B
↓ 298.46%
Q3 FY22Q/Q Change
Operating Cash Flow
2.0B
↑ 0.5%
Investing Cash Flow
-515.0M
↑ 28.75%
Financing Cash Flow
-230.0M
↓ 80.17%
Q4 FY22Q/Q Change
Operating Cash Flow
2.5B
↑ 26.42%
Investing Cash Flow
-2.2B
↑ 333.79%
Financing Cash Flow
-906.0M
↑ 293.91%
Q1 FY23Q/Q Change
Operating Cash Flow
1.9B
↓ 23.38%
Investing Cash Flow
-304.0M
↓ 86.39%
Financing Cash Flow
-262.0M
↓ 71.08%
Q2 FY23Q/Q Change
Operating Cash Flow
1.9B
↓ 1.08%
Investing Cash Flow
-431.0M
↑ 41.78%
Financing Cash Flow
-208.0M
↓ 20.61%
Q3 FY23Q/Q Change
Operating Cash Flow
1.7B
↓ 13.19%
Investing Cash Flow
-1.1B
↑ 146.87%
Financing Cash Flow
2.4B
↓ 1274.52%

Technicals Summary

Sell

Neutral

Buy

Danaher Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • Vanguard Group Inc

    7.55%

  • BlackRock Inc

    6.86%

  • Wellington Management Company LLP

    3.77%

  • State Street Corporation

    3.71%

  • FMR Inc

    3.02%

  • Morgan Stanley - Brokerage Accounts

    2.65%

Corporate Announcements

  • Danaher Corp. Dividends March,2024

    In the quarter ending March,2024. Danaher Corp. has declared dividend of $0.27

    Read More

Company Information

Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.

Organization
Danaher Corp.
Employees
61000
CEO
Mr. Steven M. Rales
Industry
Health Technology

Discover More

FAQs